Advances in PET imaging of cancer
J Schwenck, D Sonanini, JM Cotton… - Nature Reviews …, 2023 - nature.com
Molecular imaging has experienced enormous advancements in the areas of imaging
technology, imaging probe and contrast development, and data quality, as well as machine …
technology, imaging probe and contrast development, and data quality, as well as machine …
Small-molecule probes from bench to bedside: advancing molecular analysis of drug–target interactions toward precision medicine
Over the past decade, remarkable advances have been witnessed in the development of
small-molecule probes. These molecular tools have been widely applied for interrogating …
small-molecule probes. These molecular tools have been widely applied for interrogating …
PET molecular imaging in drug development: the imaging and chemistry perspective
Positron emission tomography with selective radioligands advances the drug discovery and
development process by revealing information about target engagement, proof of …
development process by revealing information about target engagement, proof of …
[HTML][HTML] Monoclonal antibody-based molecular imaging strategies and theranostic opportunities
N Dammes, D Peer - Theranostics, 2020 - ncbi.nlm.nih.gov
Molecular imaging modalities hold great potential as less invasive techniques for diagnosis
and management of various diseases. Molecular imaging combines imaging agents with …
and management of various diseases. Molecular imaging combines imaging agents with …
In vitro and in vivo NIR fluorescence lifetime imaging with a time-gated SPAD camera
Near-infrared (NIR) fluorescence lifetime imaging (FLI) provides a unique contrast
mechanism to monitor biological parameters and molecular events in vivo. Single-photon …
mechanism to monitor biological parameters and molecular events in vivo. Single-photon …
The future of nuclear medicine as an independent specialty
J Czernin, I Sonni, A Razmaria… - Journal of Nuclear …, 2019 - Soc Nuclear Med
In this article, we provide an overview of established and emerging conventional nuclear
medicine and PET imaging biomarkers, as the diagnostic nuclear medicine portfolio is …
medicine and PET imaging biomarkers, as the diagnostic nuclear medicine portfolio is …
89Zr-DFO-Durvalumab PET/CT before durvalumab treatment in patients with recurrent or metastatic head and neck cancer
SR Verhoeff, PP van de Donk… - Journal of Nuclear …, 2022 - Soc Nuclear Med
In this PD-L1 ImagiNg to prediCt durvalumab treatment response in SCCHN (PINCH) study,
we performed 89Zr-DFO-durvalumab (anti–PD-L1 [programmed death ligand 1]) PET/CT in …
we performed 89Zr-DFO-durvalumab (anti–PD-L1 [programmed death ligand 1]) PET/CT in …
Positron emission tomography imaging of the endocannabinoid system: opportunities and challenges in radiotracer development
The endocannabinoid system (ECS) is involved in a wide range of biological functions and
comprises cannabinoid receptors and enzymes responsible for endocannabinoid synthesis …
comprises cannabinoid receptors and enzymes responsible for endocannabinoid synthesis …
First-in-Human Study of the Biodistribution and Pharmacokinetics of 89Zr-CX-072, a Novel Immunopet Tracer Based on an Anti–PD-L1 Probody
L Kist de Ruijter, JS Hooiveld-Noeken, D Giesen… - Clinical Cancer …, 2021 - AACR
Abstract Purpose: CX-072, a PD-L1–targeting Probody therapeutic, is engineered to be
activated by tumor proteases that remove a masking peptide. To study effects on …
activated by tumor proteases that remove a masking peptide. To study effects on …
Radioactive polymeric nanoparticles for biomedical application
Nowadays, emerging radiolabeled nanosystems are revolutionizing medicine in terms of
diagnostics, treatment, and theranostics. These radionuclides include polymeric …
diagnostics, treatment, and theranostics. These radionuclides include polymeric …